

Literatura ACTA MEDICINAE 8–9/2023 Pneumoonkologie | Pneumologie

- 2 **Léčba časných stadií nemalobuněčného karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 2 **Přínos sekvenování nové generace v terapii nemalobuněčného plicního karcinomu – zaměřeno na rezistence u EGFR mutovaného nemalobuněčného plicního karcinomu**
MUDr. Petra Zemanová Onkologická klinika VFN a 1. LF UK, TRN VFN a 1. LF UK, Praha
MUDr. Ludmila Křížová | doc. MUDr. Milada Zemanová, Ph.D. | MUDr. Jan Špaček, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 2 **Léčba pokročilého a metastazujícího nemalobuněčného karcinomu plic bez řídicích mutací**
MUDr. Markéta Černovská Pneumologická klinika 1. LF UK a Fakultní Thomayerova nemocnice, Praha
- 3 **Rozvoj specifické imunitní odpovědi, vyšetření protilátek a jejich interpretace**
prof. MUDr. Vojtěch Thon, Ph.D. RECETOX, Masarykova univerzita a AKIMED, Brno
- 3 **Očkování proti pneumokokům u pneumologických pacientů**
doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
- 3 **Dlouhodobá léčba chronické obstrukční plicní nemoci z pohledu nového doporučení**
doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, Praha
- 3 **Domácí neinvazivní ventilace u pacientů s chronickou obstrukční plicní nemocí**
doc. MUDr. Milan Sova, Ph.D. Klinika nemocí plicních a TBC, FN Brno a LF MU, Klinika plicních nemocí a TBC, FN Olomouc a LF UP v Olomouci
MUDr. Samuel Genzor, Ph.D. | MUDr. Jan Mizera Klinika plicních nemocí a TBC, FN Olomouc a LF UP v Olomouci
MUDr. Ondřej Zela Plicní oddělení Nemocnice ve Frýdku-Místku
- 4 **Léčba idiopatické plicní fibrózy – pokroky v uplynulých pěti letech**
doc. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Pneumologická klinika 1. LF UK a FTN, Praha
- 4 **Léčba pacienta s idiopatickou plicní fibrózou a s četnými komorbiditami – kazuistika**
MUDr. Kamil Kleňha Plicní, TBC a onkologické oddělení, Nemocnice Tábor
- 4 **Komunitní pneumonie – aktuální přístup k léčebné péči**
MUDr. Petr Jakubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF UP, Olomouc
- 5 **Biologická léčba těžkého astmatu**
MUDr. Beáta Hutýrová, Ph.D. Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc
- 5 **Význam vhodné aplikační formy v kontrole onemocnění spojených s obstrukcí dolních cest dýchacích**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

Léčba časných stadií nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Spicer, J. – Wang, C. – Tanaka, F., et al.: Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2021, 39, suppl., s. 8503–8503.
- 2 Forde, P. M. – Spicer, J. – Lu, S., et al.: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N Engl J Med*, 2022, 386, s. 1973–1985.
- 3 Girard, N. – Spicer, J. – Provencio, M., et al.: Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIa) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. *Cancer Research*, 2022, 82, suppl., s. CT012-CT012.
- 4 Heymach, J. V. – Harpole, D. – Mitsudomi, T., et al.: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. AACR Annual meeting, duben 2023, abstrakt CT005.
- 5 Wakelee, H. A. – Altorki, N. K. – Zhou, C., et al.: IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC). Prezentováno na 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, 4.–8. 6. 2021, abstrakt 8500.
- 6 Paz-Ares, L. – O'Brien, M. E. R. – Mauer, M., et al.: VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. 2022. doi.org/10.1016/j.jannonc.2022.02.224.
- 7 Herbst, R. S. – Tsuboi, M. – John, T., et al.: Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIa EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Doi: 10.1200/JCO.2020.38.18_suppl.LBA.
- 8 Wu, Y.-L. – Tsuboi, M. – He, L., et al.: Osimertinib in resected EGFR-mutated non-small-cell lung cancer. *N Engl J Med*, 2020, 383, s. 1711–1723.
- 9 Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. Dostupné z: <https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html>, vyhledáno 30. 5. 2023.
- 10 Felip et al.: IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC, prezentováno na WCLC 2022.

Přínos sekvenování nové generace v terapii nemalobuněčného plicního karcinomu – zaměřeno na rezistence u EGFR mutovaného nemalobuněčného plicního karcinomu

MUDr. Petra Zemanová Onkologická klinika VFN a 1. LF UK, TRN VFN a 1. LF UK, Praha

MUDr. Ľudmila Krížová | doc. MUDr. Milada Zemanová, Ph.D. | MUDr. Jan Špaček, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 Fitzmaurice, C. – Dicker, D. – Pain, A., et al.: The global burden of cancer 2013. *JAMA Oncol*, 2015, 1, s. 505–527.
- 2 Rizzo, J. M. – Buck, M. J.: Key principles and clinical applications of 'next-generation' DNA sequencing. *Cancer Prev Res*, 2012, 5, s. 887–900.
- 3 Mosele, F. – Remon, J. – Mateo, J., et al.: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*, 2020, 31, s. 1491–1505.
- 4 Dundr, P. – Matěj, R. – Ryska, A.: The possibilities of molecular testing of static aberrations in tumor tissue using NGS in routine practice – current situation in the Czech Republic. *Česk Patol*, 2021, 57, s. 147–149.
- 5 Bonanno, L. – Dal Maso, A. – Pavan, A., et al.: Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? *Br J Cancer*, 2022, 127, s. 383–393.
- 6 Kris, M. G. – Johnson, B. E. – Berry, L. D., et al.: Using multiplexed assay of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*, 2014, 311, s. 1998–2006.
- 7 Cheng, Y. – Zhang, T. – Xu, Q.: Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. *Med Comm*, 2021, 2, s. 692–729.
- 8 Santoni-Rugiu, E. – Melchior, L. C. – Urbanska, E. M., et al.: Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. *Cancers*, 2019, 11, s. 923.
- 9 Camidge, D. R. – Pao, W. – Sequist, L. V.: Acquired resistance to TKIs in solid tumours: learning from lung cancer. *Nat Rev Clin Oncol*, 2014, 11, s. 473–481.
- 10 Cortot, A. B. – Janne, P. A.: Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. *Eur Respir Rev*, 2014, 23, s. 356–366.
- 11 Ramalingam, S. S. – Yang, J. C. – Lee, C. K., et al.: Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. *J Clin Oncol*, 2018, 36, s. 841–849.
- 12 Ramalingam, S. S. – Vansteenkiste, J. – Planchard, D., et al.: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med*, 2020, 382, s. 41–50.
- 13 Oxnard, G. R. – Hu, Y. – Mileham, K. F., et al.: Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. *JAMA Oncol*, 2018, 4, s. 1527–1534.
- 14 Yang, Z. – Yang, N. – Ou, Q., et al.: Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. *Clin Cancer Res*, 2018, 24, s. 3097–3107.
- 15 Schalm, S. S. – Dineen, T. – Lim, S. M., et al.: 384P—BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. *Ann Oncol*, 2020, 31, s. S1386–S1406.
- 16 Nishino, M. – Suda, K. – Kobayashi, Y., et al.: Effects of secondary EGFR mutations on resistance against up front osimertinib in cell s with EGFR-activating mutations in vitro. *Lung Cancer*, 2018, 126, s. 149–155.
- 17 Oxnard, G. R. – Lo, P. C. – Nishino, M., et al.: Natural history and molecular characteristics of lung cancer harboring EGFR exon 20 insertions. *J Thorac Oncol*, 2013, 8, s. 179–184.
- 18 Vyse, S. – Huang, P. H.: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. *Sig Transduct Target Ther*, 2019, 4, s. 5.
- 19 Vyse, S. – Huang, P. H.: Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. *Expert Rev Anticancer Ther*, 2022, 22, s. 3–16.
- 20 Park, K. – Haura, E. B. – Leigh, N. B., et al.: Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSLIS phase I study. *J Clin Oncol*, 2021, 39, s. 3391–3402.
- 21 Zhou, C. – Ramalingam, S. S. – Kim, T. M., et al.: Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label non randomized clinical trial. *JAMA Oncol*, 2021, 7, s. e214761.
- 22 Yang, J. C.-H. – Wang, M. – Mitchell, P., et al.: Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR exon 20 insertion mutations. *J Clin Oncol*, 2021, 39, s. 9008.
- 23 Le, X. – Goldman, J. W. G. – Clarke, J. M., et al.: Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. *J Clin Oncol*, 2020, 38, s. 9514.
- 24 Koulouris, A. – Tsagkaris, C. – Corriero, A. C., et al.: Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. *Cancers*, 2022, 14, s. 3337.
- 25 Leonetti, A. – Sharma, S. – Minari, R., et al.: Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br J Cancer*, 2019, 121, s. 725–737.
- 26 Sequist, L. V. – Han, J. Y. – Ahn, M. J., et al.: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study. *Lancet Oncol*, 2020, 21, s. 373–386.
- 27 Wu, Y.-L. – Zhang, L. – Kim, D. W., et al.: Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dys regulated non-small-cell lung cancer. *J Clin Oncol*, 2018, 36, s. 3101–3109.
- 28 Wu, Y.-L. – Cheng, Y. – Zhou, J., et al.: Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET over expression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT Study): an open-label, phase 1b/2, multicentre, randomised trial. *Lancet Respir Med*, 2020, 8, s. 1132–1143.
- 29 Li, B. T. – Smit, E. F. – Goto, Y., et al.: DESTINY-Lung 01 Trial Investigators: Trastuzumab Deruxetecan in HER2-mutant non-small-cell lung cancer. *N Engl J Med*, 2022, 386, s. 241–251.
- 30 Janne, P. A. – Baik, C. – Su, W. C., et al.: Efficacy and safety of patritumab deruxetecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. *Cancer Discov*, 2022, 12, s. 74–89.
- 31 Mazieres, J. – Lafitte, C. – Ricordel, C., et al.: Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. *J Clin Oncol*, 2022, 40, s. 719–728.
- 32 Le, X. – Cornelissen, R. – Garassino, M., et al.: Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH2-02 trial. *J Clin Oncol*, 2022, 40, s. 710–771.
- 33 Planchard, D. – Besse, B. – Groen, H. J. M., et al.: Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. *J Thorac Oncol*, 2022, 17, s. 103–115.
- 34 La Monica, S. – Fumarola, C. – Cretella, D., et al.: Efficacy of the CDK4/6 dual inhibitor abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to osimertinib. *Cancers*, 2020, 13, s. 6.
- 35 Qin, Q. – Li, X. – Liang, X., et al.: CDK4/6 inhibitor palbociclib over come acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). *Thorac Cancer*, 2020, 11, s. 2389–2397.
- 36 Reck, M. – Mok, M. – Socinski, M. A., et al.: 1293P IMpower150: updated efficacy analysis in patients with EGFR mutations. *Ann Oncol*, 2020, 31, s. S837–S838.
- 37 Shin, H. G. – Yang, H. R. – Yoon, A., et al.: Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy. *Int J Mol Sci*, 2022, 23, s. 5686.

Léčba pokročilého a metastazujícího nemalobuněčného karcinomu plic bez řídicích mutací

MUDr. Markéta Černovská Pneumologická klinika 1. LF UK a Fakultní Thomayerova nemocnice, Praha

- 1 Vafaei, S. – Zekiy, A. O. – Khanamir, R. A., et al.: Combination therapy with immune checkpoint inhibitors (ICIs): a new frontier. *Cancer Cell Int*, 2022, 22, s. 2.
- 2 Petruželka L.: Precizní imunoterapie solidních nádorů – současný stav a pohled do budoucnosti. *Remedia*, 2020, 31.
- 3 Reck, M. – Rodríguez-Abreu, D. – Robinson, A., et al.: Updated

- analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. *J Clin Oncol*, 2019, 37, s. 537–546.
- Villegas, A. – Daniel, D., et al.: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *New Engl J Med*, 2018, 379, s. 2342–2350.
 - Spigel, D.: Durvalumab improves 5-year OS and PFS in patients with unresectable stage III NSCLC. ASCO Annual Meeting. 7. 6. 2021.
 - Paz-Ares, L. G. – Ciuleanu, T. – Cobo-Dols, M., et al.: First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from Check Mate 9LA. *J Clin Oncol*, 2022, 40, suppl. 17, s. LBA9026.
 - Kirkwood, J. M.: Effects of immunotherapy and targeted therapy on melanoma survival curves. Download Scientific Diagram. Dostupné z: https://www.researchgate.net/figure/Effects-of-immunotherapy-and-targeted-therapy-on-melanoma-survival-curves_fig1_51853947, vyhledáno 5. 4. 2023.
 - SPC LP Keytruda. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?kod=0209484>, vyhledáno 5. 4. 2023.
 - Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0209484&tab=prices>, vyhledáno 5. 4. 2023.
 - Quinn, C. – Garrison, L. P. – Pownell, A. K., et al.: Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. *J Immunother Cancer*, 2020, 8, s. e000648.
 - Sezer, A. – Kilickap, S. – Gümüş, M., et al.: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet*, 2021, 397, s. 592–604.
 - Hellmann, M. D. – Paz-Ares, L. – Bernabe Caro, R., et al.: Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N Engl J Med*, 2019, 381, s. 2020–2031.
 - Herbst, R. S. – Giaccone, G. – de Marinis, F., et al.: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med*, 2020, 383, s. 1328–1339.
 - Gadgeel, S. – Rodríguez-Abreu, D. – Speranza, G., et al.: Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pembrolizumab and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. *J Clin Oncol*, 2020, 38, s. 1505–1517.

Rozvoj specifické imunitní odpovědi, vyšetření protilátek a jejich interpretace

prof. MUDr. Vojtěch Thon, Ph.D. RECETOX, Masarykova univerzita a AKIMED, Brno

- Thon, V.: Intestinální mikroflóra v raném dětství – úloha při rozvoji infekčních a alergických chorob. *Pediatr Praxi*, 2011, 12, s. 252–256.
- Tlaskalová-Hogenová, H. – Tuckova, L. – Mestecky, J., et al.: Interaction of mucosal microbiota with the innate immune system. *Scand J Immunol*, 2005, 62, suppl. 1, s. 106–113.
- Brandtzaeg, P. – Kiyono, H. – Pabst, R., et al.: Terminology: nomenclature of mucosa-associated lymphoid tissue. *Mucosal Immunol*, 2008, 1, s. 31–37.
- Tlaskalová-Hogenová, H. – Stěpánková, R. – Kozáková, H., et al.: The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol Immunol*, 2011, 8, s. 110–120.
- Pivrcová, E. – Kotásková, I. – Thon, V.: Neonatal diet and gut microbiome development after C-section during the first three months after birth: a systematic review. *Front Nutr*, 2022, 9, s. 941549.
- Hamanova, M. – Chmelíková, M. – Nentwich, I. – Thon, V. – Lokaj, J.: Anti-Gal IgM, IgA and IgG natural antibodies in childhood. *Immunol Lett*, 2015, 164, s. 40–43.
- Thon, V.: Dítě s imunodeficientním stavem, možnosti řešení. 1. část. Diagnostické přístupy. *Pediatr Praxi*, 2014, 15, s. 138–140.
- Thon, V.: Dítě s imunodeficientním stavem, možnosti řešení. 2. část. Léčba a novorozenecký screening. *Pediatr Praxi*, 2014, 15, s. 254–256.
- Speckmann, C. – Nennstiel, U. – Höing, M., et al.: Prospective newborn screening for SCID in Germany: a first analysis by the Pediatric Immunology Working Group (API). *J Clin Immunol*, 2023, 43, s. 965–978.
- Wakamatsu, M. – Kojima, D. – Muramatsu, H., et al.: TREC/KREC newborn screening followed by next-generation sequencing for severe combined immunodeficiency in Japan. *J Clin Immunol*, 2022, 42, s. 1696–1707.
- Boyle, J. M. – Buckley, R. H.: Population prevalence of diagnosed primary immunodeficiency diseases in the United States. *J Clin Immunol*, 2007, 27, s. 497–502.
- de Vries, E.: European Society for Immunodeficiencies (ESID) members: Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. *Clin Exp Immunol*, 2012, 167, s. 108–119.
- Markus, G.: ESID Registry – Working definitions for clinical diagnosis of PID. ESID, 2019. Dostupné z <https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria>, vyhledáno 26. 6. 2023.
- Hoernes, M. – Seger, R. – Reichenbach, J.: Modern management of primary B-cell immunodeficiencies. *Pediatr Allergy Immunol*, 2011, 22, s. 758–769.
- Thon, V. – Vlková, M. – Chovancová, Z., et al.: Flow based enumeration of plasmablasts in peripheral blood after vaccination as a novel diagnostic marker for assessing antibody responses in patients with hypogammaglobulinemia. In: M. Sc. Ingrid Schmid (ed.): *Clinical Flow Cytometry – Emerging Applications*. InTech, 2012, s. 125–142.
- Bruton, O. C.: Agammaglobulinemia. *Pediatrics*, 1952, 9, s. 722–728.
- Gathmann, B. – Mahlaoui, N. – Ceredih, G. L., et al.: European Society for Immunodeficiencies Registry Working Party: Clinical picture and treatment of 2212 patients with common variable immunodeficiency. *J Allergy Clin Immunol*, 2014, 134, s. 116–126.
- Thon, V. – Wolf, H. M. – Sasgary, M., et al.: Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. *Clin Exp Immunol*, 1997, 110, s. 174–181.
- Cavaliere, F. M. – Milito, C. – Martini, H., et al.: Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. *J Clin Immunol*, 2013, 33, s. 838–846.
- Bronson, P. G. – Chang, D. – Bhargale, T., et al.: Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are associated with selective IgA deficiency. *Nat Genet*, 2016, 48, s. 1425–1429.
- Horn, J. – Thon, V. – Bartonkova, D., et al.: Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. *Clin Immunol*, 2007, 122, s. 156–162.

Očkování proti pneumokokům u pneumologických pacientů

doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha

- Kolek, V.: Infekční pneumonie. In: Kolek, V. – Kašák, V., et al.: *Pneumologie*. Maxdorf/Jessenius, 2014, s. 121–143.
- Smetana, J. – Chlíbek, R.: Očkování pacientů s chronickým respiračním onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, 2019, s. 259–266.
- Prymula, R.: Očkování proti pneumokokovému onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, 2019, s. 150–161.
- Kozáková, J. – Okonji, Z. – Klímová, M., et al.: Invazivní pneumokoková onemocnění v České republice v roce 2019. *Zprávy centra epidemiologie a mikrobiologie*, 2020, SZÚ, Praha 2020, 29.
- Petroušová, L. – Rožnovský, L.: Pneumokoková infekce u dospělých a jejich prevence. *Med Praxi*, 2013, 10, s. 104–107.
- www.sukl.cz
- Bonten, M. J. – Huijts, S. M. – Bolkenbass, M., et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*, 2015, 372, s. 1114–1125.
- Dušek, L.: Proočkovanost v dostupných datech Národního zdravotnického informačního systému (NZIS). ÚZIS, 2019, s. 1–40. Dostupné z: <https://vyvoj.vakcinace.eu/storage/files/prednasky/2019/9.pdf>, vyhledáno 2. 5. 2023.
- Pittet, L. F. – Posfay-Barbe, K. M.: Pneumococcal vaccines for children: a global public health priority. *Clin Microbiol Infect*, 2012, 18, s. 25–36.
- SPC Prevenar. Dostupné z: <https://vakciny.avenier.cz/userfiles/file/prevenar-13-spc.pdf>, vyhledáno 2. 5. 2023.

Dlouhodobá léčba chronické obstrukční plicní nemoci z pohledu nového doporučení

doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, Praha

- Global Strategy for Diagnosis, Management and Prevention of COPD 2023 Report, www.goldcopd.org.
- Lipson, D. A., et al.: Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2020, 201, s. 1508–1516.
- Martinez, F. J., et al.: Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. *Am J Respir Crit Care Med*, 2021, 203, s. 553–564.
- Zatloukal, J., et al.: Chronická obstrukční plicní nemoc – diagnóza a léčba stabilní nemoci; personalizovaný přístup k péči, využívající koncept léčitelných charakteristik, založený na klinických fenotypech. Poziční dokument ČPFS. *Stud Pneumol Phthisiol*, 2023, 83, s. 45–80.

Domácí neinvazivní ventilace u pacientů s chronickou obstrukční plicní nemocí

doc. MUDr. Milan Sova, Ph.D. Klinika nemocí plicních a TBC, FN Brno a LF MU, Klinika plicních nemocí a TBC, FN Olomouc a LF UP v Olomouci

MUDr. Samuel Genzor, Ph.D. | MUDr. Jan Mizera Klinika plicních nemocí a TBC, FN Olomouc a LF UP v Olomouci

MUDr. Ondřej Zela Plicní oddělení Nemocnice ve Frýdku-Místku

- 2023 Gold Report. Global Initiative for prevention, diagnosis and management of COPD: 2023 Report. Dostupné z <https://goldcopd.org/2023-gold-report-2/>, vyhledáno 2. 6. 2023.
- Bouloukaki, I. – Fanaridis, M. – Testelmans, D., et al.: Overlaps between obstructive sleep apnoea and other respiratory diseases, including COPD, asthma and interstitial lung disease. *Breathe*, 2022, 18, s. 220073.
- McNicholas, W. T.: Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease. *J Thorac Dis*, 2018, 10, suppl. 34, s. S4253–S4261.
- Shawon, M. S. – Perret, J. L. – Senaratna, C. V., et al.: Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep

apnea and chronic obstructive pulmonary disease: a systematic review. *Sleep Med Rev*, 2017, 32, s. 58–68.

5 **Adler, D. – Bailly, S. – Benmerad, M., et al.:** Clinical presentation and comorbidities of obstructive sleep apnea-COPD overlap syndrome. *PLoS One*, 2020, 15, e0235331.

6 **Shah, A. J. – Quek, E. – Alqahtani, J. S., et al.:** Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: a systematic review and meta-analysis. *Sleep Med Rev*, 2022, 63, s. 101627.

7 **Macrea, M. – Oczkowski, S. – Rochweg, B., et al.:** Long-term non-invasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease. An official American Thoracic Society clinical

practice guideline. *Am J Respir Crit Care Med*, 2020, 202, s. e74–e87.

8 **Roberts, C. M. – Stone, R. A. – Buckingham, R. J., et al.:** Acidosis, non-invasive ventilation and mortality in hospitalised COPD exacerbations. *Thorax*, 2011, 66, s. 43–48.

9 **Chu, C. M. – Chan, V. L. – Lin, A. W., et al.:** Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. *Thorax*, 2004, 59, s. 1020–1025.

10 **Lněnička, J. – Dostálová, S. – Doušová, T., et al.:** Doporučený postup domácí neinvazivní ventilace. *Stud Pneumol Phthiseol*, 2022, 82, s. 168–184.

11 **Murphy, P. B. – Rehal, S. – Arbane, G., et al.:** Effect of home non-invasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. *JAMA*, 2017, 317, s. 2177–2186.

12 **Lumis 150 VPAP ST-A.** Dostupné z: <https://www.resmed.cz/odborne/lumis-150-vpap-st-a>, vyhledáno 2. 6. 2023.

13 **AirFit N20.** Dostupné z: <https://www.resmed.cz/airfit-n20>, vyhledáno 2. 6. 2023.

14 **Aktualizovaný dotazník STOP Bang.** Dostupné z: <http://www.stop-bang.ca/translation/pdf/czech.pdf>, vyhledáno 2. 6. 2023.

Léčba idiopatické plicní fibrózy – pokroky v uplynulých pěti letech

doc. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Pneumologická klinika 1. LF UK a FTN, Praha

1 **IpF treatment – SearchResults – PubMed.** Dostupné z: [nih.gov](https://pubmed.ncbi.nlm.nih.gov/), vyhledáno 10. 5. 2023.

2 **Maier, T. M. – Ford, P. – Brown, K. K., et al.:** ISABELA 1 and 2 Investigators: Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: The ISABELA 1 and 2 randomized clinical trials. *JAMA*, 2023, 329, s. 1567–1578.

3 **Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO).** ClinicalTrials.gov. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01915511>, vyhledáno 10. 5. 2023.

4 **Raghu, G. – Remy-Jardin, M. – Richeldi, L., et al.:** Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med*, 2022, 205, s. e18–e47.

5 **Choudhary, S. – Weight, S. S. – Ribeiro Neto, M. L., et al.:** Interstitial lung disease progression after genomic usual interstitial pneumonia testing. *Eur Respir J*, 2023, 61, s. 2201245.

6 **Allen, R. J. – Guillen-Guio, B. – Oldham, J. M., et al.:** Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*, 2020, 201, s. 564–574.

7 **Partanen, J. J. – Häppölä, P. – Zhou, W., et al.:** Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. *Cell Genom*, 2022, 2, s. 100181, doi: 10.1016/j.

xgen.2022.100181. PMID: 36777997; PMCID: PMC9903787.

8 **Cottin, V. – Bonniaud, P. – Cadranet, J., et al.:** Recommendations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version intégrale [French practical guidelines for the diagnosis and management of IPF – 2021 update, full version]. *Rev Mal Respir*, 2022, 39, s. e35–e106.

9 **Oldham, J. M. – Ma, S. F. – Martínez, F. J., et al.:** IPF net Investigators: TOLLIP, MUC5B, and the response to N-acetyl cysteine among individuals with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*, 2015, 192, s. 1475–1482.

10 **Podolanczuk, A. J. – Kim, J. S. – Cooper, C. B., et al.:** PRECISIONS Study Team: Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. *BMC Pulm Med*, 2022, 22, s. 475.

11 **Tirelli, C. – Pesenti, C. – Miozzo, M., et al.:** The genetic and epigenetic footprint in idiopathic pulmonary fibrosis and familial pulmonary fibrosis: a state-of-the-art review. *Diagnostics*, 2022, 12, s. 3107.

12 **Behr, J. – Prasse, A. – Wirtz, H., et al.:** Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. *Eur Respir J*, 2020, 56, s. 1902279.

13 **Ma, Y. – Cui, F. – Li, D., et al.:** Lifestyle, genetic susceptibility, and the risk of idiopathic pulmonary fibrosis: a large prospective cohort study. *Chest*, 2023, 50012-3692(23)00504-4.

14 **Leard, L. E. – Holm, A. M. – Valapour, M., et al.:** Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*, 2021, 40, s. 1349–1379.

15 **Alder, J. K. – Sutton, R. M. – Isabella, C. J., et al.:** Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease. *J Heart Lung Transplant*, 2022, 41, s. 654–663.

16 **Wang, P. – Leung, J. – Lam, A., et al.:** Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses. *J Heart Lung Transplant*, 2022, 41, s. 641–653.

17 **Waxman, A. – Restrepo-Jaramillo, R. – Thenappan, T., et al.:** Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. *N Engl J Med*, 2021, 384, s. 325–334.

18 **Nathan, S. D. – Waxman, A. – Rajagopal, S., et al.:** Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. *Lancet Respir Med*, 2021, 9, s. 1266–1274.

19 **Nathan, S. D. – Behr, J. – Cottin, V., et al.:** Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. *BMJ Open Respir Res*, 2022, 9, s. e001310.

Léčba pacienta s idiopatickou plicní fibrózou a s četnými komorbiditami – kazuistika

MUDr. Kamil Kleřha Plicní, TBC a onkologické oddělení, Nemocnice Tábor

1 **Vařáková, M. – Polák, J. – Matěj, R.:** *Intersticiální plicní procesy*. Maxdorf, Praha, 2016.

2 **SPC Ořev,** poslední revize textu 13. 10. 2021.

Komunitní pneumonie – aktuální přístup k léčebné péči

MUDr. Petr Jakubec, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF UP, Olomouc

1 **Ševčík, P. – Skříčková, J. – Šrámek, V., et al.:** *Záněty plic v intenzivní medicíně*. Galén, Praha, 2004.

2 **Kolek, V.:** *Pneumonie – diagnostika a léčba*. Triton, Praha, 2003.

3 **Torres, A. – Cillóniz, C. – Blasi, F., et al.:** Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. *Respir Med*, 2018, 137, s. 6–13.

4 **Ticona, J. H. – Zaccane, V. M. – McFarlane, I. M.:** Community-acquired pneumonia: a focused review. *Am J Med Case Rep*, 2021, 9, s. 45–52.

5 **Jain, S. – Self, W. H. – Wunderink, R. G., et al.:** CDC EPIC Study Team: Community-acquired pneumonia requiring hospitalization among U.S. Adults. *N Engl J Med*, 2015, 373, s. 415–427.

6 **Torres, A. – Peetermans, W. E. – Viegi, G., et al.:** Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax*, 2013, 68, s. 1057–1065.

7 **Karhu, J. – Ala-Kokko, T. I. – Ohtonen, P., et al.:** Severe community-acquired pneumonia treated with β -lactam-respiratory quinolone vs. β -lactam-macrolide combination. *Acta Anaesthesiol Scand*, 2013, 57, s. 587–593.

8 **Ewig, S. – Woodhead, M. – Torres, A.:** Towards a sensible comprehension of severe community-acquired pneumonia. *Intensive Care Med*, 2011, 37, s. 214–223.

9 **Shi, T. – Denouel, A. – Tietjen, A. K., et al.:** Global and regional burden of hospital admissions for pneumonia in older adults: a systematic review and meta-analysis. *J Infect Dis*, 2020, 222, s. S570–S576.

10 **Cillóniz, C. – Ewig, S. – Polverino, E., et al.:** Community-acquired pneumonia in outpatients: aetiology and outcomes. *Eur Respir J*, 2012, 40, s. 931–938.

11 **Johansson, N. – Kalin, M. – Tiveljung-Lindell, A., et al.:** Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. *Clin Infect Dis*, 2010, 50, s. 202–209.

12 **Gadsby, N. J. – Russell, C. D. – McHugh, M. P., et al.:** Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. *Clin Infect Dis*, 2016, 62, s. 817–823.

13 **Sahuquillo-Arce, J. M. – Menéndez, R. – Méndez, R., et al.:** Age-related risk factors for bacterial aetiology in community-acquired pneumonia. *Respirology*, 2016, 21, s. 1472–1479.

14 **Prina, E. – Ranzani, O. T. – Polverino, E., et al.:** Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. *Ann Am Thorac Soc*, 2015, 12, s. 153–160.

15 **Karhu, J. – Ala-Kokko, T. I. – Vuorinen, T., et al.:** Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. *Clin Infect Dis*, 2014, 59, s. 62–70.

16 **Wu, X. – Wang, Q. – Wang, M., et al.:** Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. *Respiration*, 2015, 89, s. 343–352.

17 **Shoar, S. – Musher, D. M.:** Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia*, 2020, 12, s. 11.

18 **Johansson, N. – Kalin, M. – Hedlund, J.:** Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. *Scand J Infect Dis*, 2011, 43, s. 609–615.

19 **Mandell, L. A. – Wunderink, R. G. – Anzueto, A., et al.:** IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*, 2007, 44, s. 27–72.

20 **Macfarlane, J. T. – Boswell, T. – Douglas, G., et al.:** BTS guidelines for the management of community acquired pneumonia in adults. *Thorax*, 2001, 56, s. 1–64.

21 **Bauer, T. T. – Ewig, S. – Marre, R., et al.:** CRB-65 predicts death from community-acquired pneumonia. *J Intern Med*, 2006, 260, s. 93–101.

22 **Marti, C. – Garin, N. – Grosgrin, O., et al.:** Prediction of severe

community-acquired pneumonia: a systematic review and meta-analysis. *Critical Care*, 2012, 16, s. R141.

23 **Liapikou, A. – Ferrer, M. – Polverino, E., et al.:** Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. *Clin Infect Dis*, 2009, 48, s. 377–385.

24 **Espana, P. P. – Capelastegui, A. – Gorordo, I., et al.:** Development and validation of a clinical prediction rule for severe community-acquired pneumonia. *Am J Respir Crit Care Med*, 2006, 174, s. 1249–1256.

25 **Charles, P. G. – Wolfe, R. – Whitby, M., et al.:** SMART-COP: a tool for predicting the need for intensive respiratory and vasopressor support in community-acquired pneumonia. *Clin Infect Dis*, 2008, 47, s. 375–384.

26 **Asai, N. – Watanabe, H. – Shiota, A., et al.:** Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia. *Int J Infect Dis*, 2019, 84, s. 89–96.

27 **De Pascale, G. – Bello, G. – Tumbarello, M., et al.:** Severe pneumonia in intensive care. Cause, diagnosis, treatment and management: a review of the literature. *Curr Opin Pulm Med*, 2012, 18, s. 213–221.

28 **Garin, N. – Marti, C.:** Community-acquired pneumonia: the elusive quest for the best treatment strategy. *J Thorac Dis*, 2016, 8, s. E571–E574.

29 **Lee, J. S. – Giesler, D. L. – Gellad, W. F., et al.:** Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. *JAMA*, 2016, 315, s. 593–602.

30 **Dellinger, R. P.:** A lifetime of critical care: changes. *Crit Care Med*, 2016, 44, s. 653–654.

31 **Gattarello, S. – Lagunes, L. – Vidaur, L., et al.:** Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal

- community-acquired pneumonia: a matched case-control study. *Crit Care*, 2015, 19, s. 335.
- 32 **Metlay, J. P. – Waterer, G. W. – Long, A. C., et al.**: Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*, 2019, 200, s. e45–e67.
- 33 **Woodhead, M. – Blasi, F. – Ewig, S., et al.**: Guidelines for the management of adult lower respiratory tract infections – full version. *Clin Microbiol Infect*, 2011, 17, suppl. 6, s. E1–59.
- 34 **Tansarli, G. S. – Mylonakis, E.**: Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. *Antimicrob Agents Chemother*, 2018, 62, s. e00635–18.
- 35 **Dinh, A. – Crémieux, A. C. – Guillemot, D.**: Short treatment duration for community-acquired pneumonia. *Curr Opin Infect Dis*, 2023, 36, s. 140–145.
- 36 **Kolek, V. – Kolář, M. – Kašák, V., et al.**: Diagnostika a léčba komunitní pneumonie dospělých. In: Kolek, V., et al.: *Doporučené postupy v pneumologii*. Maxdorf, Praha, 2013, s. 107–123.
- 37 **Jakubec, P. – Kolek, V. – Kolář, M.**: Diagnostika a léčba těžké pneumonie. In: Kolek, V., et al.: *Doporučené postupy v pneumologii*. Maxdorf, Praha, 2013, s. 124–140.
- 38 **Sligh, W. I. – Asadi, L. – Eurich, D. T., et al.**: Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. *Crit Care Med*, 2014, 42, s. 420–432.
- 39 **Vardakas, K. Z. – Trigkidis, K. K. – Falagas, M. E.**: Fluoroquinolones or macrolides in combination with beta-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. *Clin Microbiol Infect*, 2017, 23, s. 234–241.
- 40 **Nair, G. B. – Niederman, M. S.**: Updates on community acquired pneumonia management in the ICU. *Pharmacol Ther*, 2021, 217, doi: 10.1016/j.pharmthera.2020.107663.
- 41 **Barberán, J. – Restrepo, R. – Cardinal-Fernández, P.**: Community-acquired pneumonia: similarities and differences between European and American guidelines – A narrative review. *Rev Esp Quimioter*, 2021, 34, s. 72–80.
- 42 **Frat, J. P. – Arnaud, W. – Thille, A. W., et al.**: High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*, 2015, 372, s. 2185–2196.
- 43 **Roca, O. – Messika, J. – Caralt, B., et al.**: Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. *J Crit Care*, 2016, 35, s. 200–205.
- 44 **Ferrer, M. – Esquinas, A. – Leon, M., et al.**: Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. *Am J Respir Crit Care Med*, 2003, 168, s. 1438–1444.
- 45 **Ferrer, M. – Cosentini, R. – Nava, S.**: The use of non-invasive ventilation during acute respiratory failure due to pneumonia. *Eur J Intern Med*, 2012, 23, s. 420–428.
- 46 **Vanoni, N. M. – Carugati, M. – Borsa, N., et al.**: Management of acute respiratory failure due to community-acquired pneumonia: a systematic review. *Med Sci*, 2019, 7, s. 10.
- 47 **Carron, M. – Freo, U. – Zorzi, M., et al.**: Predictors of failure of noninvasive ventilation in patients with severe community-acquired pneumonia. *J Crit Care*, 2010, 25, s. 514–540.
- 48 **Carillo, A. – Gonzales-Diaz, G. – Ferrer, M., et al.**: Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. *Intensive Care Med*, 2012, 38, s. 458–456.
- 49 **Singer, M. – Deuschman, C. S. – Seymour, C. W., et al.**: The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA*, 2016, 315, s. 801–810.
- 50 **Evans, L. – Rhodes, A. – Alhazzani, W., et al.**: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med*, 2021, 47, s. 1181–1247.
- 51 **Ribeiro, D. D. – Lijfering, W. M. – Van Hylckama Vlieg, A., et al.**: Pneumonia and risk of venous thrombosis: results from the MEGA study. *J Thromb Haemost*, 2012, 10, s. 1179–1182.
- 52 **Martin-Loeches, I. – Lisboa, T. – Rodriguez, A., et al.**: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med*, 2010, 36, s. 612–620.
- 53 **Ceccato, A. – Cilloniz, C. – Martin-Loeches, I., et al.**: Effect of combined β -lactam/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia. *Chest*, 2019, 155, s. 795–804.
- 54 **Shorr, A. F. – Simmons, J. – Hampton, N., et al.**: Pneumococcal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance. *Respir Med*, 2021, 177, doi: 10.1016/j.rmed.2021.106307.
- 55 **Welte, T. – Dellinger, R. P. – Ebel, H., et al.**: Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). *Intensive Care Med*, 2018, 44, s. 438–448.
- 56 **Jiang, S. – Liu, T. – Hu, Y., et al.**: Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. *Medicine*, 2019, 98, s. e16239.
- 57 **Stern, A. – Skalsky, K. – Avni, T., et al.**: Corticosteroids for pneumonia. *Cochrane Database Syst Rev*, 2017, 12, CD007720.
- 58 **Briel, M. – Spoorenberg, S. M. C. – Snijders, D., et al.**: Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. *Clin Infect Dis*, 2018, 66, s. 346–354.
- 59 **Torres, A. – Sibila, O. – Ferrer, M., et al.**: Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. *JAMA*, 2015, 313, s. 677–686.
- 60 **Blum, C. A. – Nigro, N. – Briel, M., et al.**: Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*, 2015, 385, s. 1511–1518.
- 61 **Huang, J. – Guo, J. – Li, H., et al.**: Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia. *Medicine*, 2019, 98, s. e14636.
- 62 **Dequin, P. F. – Meziani, F. – Quenot, J. P., et al.**: CRICS-TRI-GGERSep Network: Hydrocortisone in severe community-acquired pneumonia. *N Engl J Med*, 2023, 388, s. 1931–1941.
- 63 **Voiriot, G. – Philippot, Q. – Elabbadi, A. – Elbim, C., et al.**: Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. *J Clin Med*, 2019, 8, s. 786.
- 64 **Basille, D. – Thomsen, R. W. – Madsen, M., et al.**: Nonsteroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia. *Am J Respir Crit Care Med*, 2018, 198, s. 128–131.

Biologická léčba těžkého astmatu

MUDr. Beáta Hutytová, Ph.D. Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc

- 1 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Dostupné z: www.ginaasthma.org. Pp 1–225. Dostupný na <https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf>, vyhledáno 2. 5. 2023.
- 2 **Busse, W. W. – Castro, M. – Casale, T. B.**: Asthma management in adults. *J Allergy Clin Immunol Pract*, 2023, 11, s. 21–33.
- 3 **Maspero, J. – Adir, Y. – Al-Ahmad, M., et al.**: Type 2 inflammation in asthma and other airway diseases. *ERJ Open Res*, 2022, 8, 00576–2021.
- 4 **Teřl, M. – Čáp, P. – Dvořáková, R., et al.**: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. Semily, GEUM, 2015.
- 5 **Buhl, R. – Bel, E. – Bourdin, A., et al.**: Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion. *J Allergy Clin Immunol Pract*, 2022, 10, s. 422–432.
- 6 **Brusselle, G. G. – Koppelman, G. H.**: Biologic therapies for severe asthma. *N Engl J Med*, 2022, 386, s. 157–171.
- 7 **Sze, E. – Bhalla, A. – Nair, P.**: Mechanisms and therapeutic strategies for non-T2 asthma. *Allergy*, 2020, 75, s. 311–325.
- 8 SÚKL, úhradová kritéria. Dostupné z: <https://www.sukl.cz/search.php?action=results&query=%C3%BAhradova%C3%A1+kriteri%C3%A1&y=0>, vyhledáno 2. 5. 2023.
- 9 **Corren, J. – Parnes, J. R. – Wang, L., et al.**: Tezepelumab in adults with uncontrolled asthma. *N Engl J Med*, 2017, 377, s. 936–946.
- 10 **Menzies-Gow, A. – Corren, J. – Bourdin, A., et al.**: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med*, 2021, 384, s. 1800–1809.
- 11 **Teřl, M. – Sedlík, V. – Krčmová, I.**: Doporučený postup diagnostiky a léčby těžkého astmatu. *Stud Pneumol Phthiseol*, 2022, 82, s. 122–127.
- 12 **Pavord, I. D. – Korn, S. – Howarth, P., et al.**: Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
- 13 **Castro, M. – Malthur, S. – Hargreave, F., et al.**: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med*, 2011, 184, s. 1125–1132.
- 14 **Bleecker, E. R. – FitzGerald, J. M. – Chanez, P., et al.**: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2115–2127.
- 15 **Cevhertas, L. – Ogulur, I. – Maurer, D. J., et al.**: Advances and recent developments in asthma in 2020. *Allergy*, 2020, 75, s. 3124–3146.
- 16 **Sugita, K. – Steer, C. A. – Martinez-Gonzalez, I., et al.**: Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. *J Allergy Clin Immunol*, 2018, 141, s. 300–310.
- 17 **Busse, W. W. – Kraft, M. – Rabe, K. F., et al.**: Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. *Eur Respir J*, 2021, 58, 2003393.
- 18 **Wenzel, S. – Castro, M. – Corren, J., et al.**: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*, 2016, 388, s. 31–44.
- 19 **Nettis, E. – Patella, V. – Lombardo, C., et al.**: Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. *Allergy*, 2020, 75, s. 2653–2661.
- 20 **Al Heialy, S. – Ramakrishnan, R. K. – Hamid, Q.**: Recent advances in the immunopathogenesis of severe asthma. *J Allergy Clin Immunol*, 2022, 149, s. 455–465.
- 21 **Menzies-Gow, A. – Corren, J. – Bourdin, A., et al.**: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med*, 2021, 384, s. 1800–1809.
- 22 **Diver, S. – Khalfaoui, L. – Emson, C., et al.**: Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*, 2021, 9, s. 1299–1312.

Význam vhodné aplikační formy v kontrole onemocnění spojených s obstrukcí dolních cest dýchacích

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Malmberg, L. P. – Everard, M. L. – Haikarainen, J., et al.**: Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler. *J Aerosol Med Pulm Drug Deliv*, 2014, 27, s. 329–340.
- 2 **Haikarainen, J. – Ryttilä, P. – Roos, S., et al.**: Dose uniformity of budesonide Easyhaler under simulated real-life conditions and with low inspiration flowrates. *Chron Respir Dis*, 2018, 15, s. 265–271.
- 3 **Lähelmä, S. – Sairanen, U. – Haikarainen, J., et al.**: Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. *J Aerosol Med Pulm Drug Deliv*, 2015, 28, s. 462–473.
- 4 **Lähelmä, S. – Vahteristo, M. – Metev, H., et al.**: Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma. *Respir Med*, 2016, 120, s. 31–35.
- 5 **Ribó, P. – Molina, J. – Calle, M., et al.**: Prevalence of modifiable factors lifting treatment efficacy of poorly controlled asthma patients: EFF-MERA observational study. *NPJ Prim Care Respir Med*, 2020, 30, s. 33.
- 6 **Tamási, L. – Szilasi, M. – Gálffy, G.**: Clinical effectiveness of budesonide/formoterol fumarate Easyhaler for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. *Adv Ther*, 2018, 35, s. 1140–1152.